Journal article
Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1 year results from two phase 3 studies
- Abstract:
-
Objectives: To evaluate 1-year bimekizumab efficacy in psoriatic arthritis (PsA) from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire.
Methods: BE OPTIMAL (NCT03895203; biologic disease-modifying antirheumatic drug [bDMARD]-naïve), BE COMPLETE (NCT03896581; inadequate response/intolerance to tumour necrosis factor inhibitors [TNFi-IR]) and BE VITAL (NCT04009499; open-label extension) assessed bimekizumab...
Expand abstract
- Publication status:
- Accepted
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Oxford University Press
- Journal:
- Rheumatology More from this journal
- Acceptance date:
- 2024-05-10
- EISSN:
-
1462-0332
- ISSN:
-
1462-0324
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1996150
- Local pid:
-
pubs:1996150
- Deposit date:
-
2024-05-14
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record